Weeks after receiving the first US Food and Drug Administration approval, Biogen, Inc. and Bio-Thera Solutions Ltd. have announced a settlement agreement that ends patent-infringement litigation with Roche over the pair’s partnered biosimilar to Actemra (tocilizumab).
Confirmation of the settlement appeared in a filing by the firms, including Roche’s partner Chugai, from the US District Court for the District of
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?